Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 701–800 of 902
PKCα is involved in phorbol ester TPA-mediated stabilization of p14ARF
Inoue, R., & Shiraishi, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.117 · Cited by 9
The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired
Becker, T. M., Ayub, A. L. P., Kefford, R. F., Mann, G. J., & Rizos, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21265 · Cited by 9
Bouvier‐Labit, Civatte, Bartoli, C., Renaud, Pellissier, & Figarella‐Branger (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00203.x · Cited by 10
Lukas, C., Jensen, S. S., Bártková, J., Lukas, J., & Bartek, J. J. (1999) · Hybridoma · doi:10.1089/027245799315871 · Cited by 9
Self-citationGuan, C., Chen, H., Chen, H., Li, S., Chen, Y., Chen, J., Dong, Y., Zheng, Z., Wang, K., & Pan, C. (2024) · Medicine · doi:10.1097/md.0000000000037229 · Cited by 8
“[41] CDKN2A was the first TSG to be inactivated in lung cancer mainly through aberrant hypermethylation.”
BackgroundChien, W. W., Catallo, R., Chebel, A., Baranger, L., Thomas, X., Béné, M. C., Gerland, L. M., Schmidt, A., Beldjord, K., Klein, N., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.01.008 · Cited by 8
CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI
Životić, I., Djurić, T., Stanković, A., Milašinović, D., Stankovic, G. R., Dekleva, M., Marković, N., Alavantić, D., & Živković, M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.003 · Cited by 8
Villa, F., Crippa, A., Pelizzoni, D., Ardizzoia, A., Scartabellati, G., Corbetta, C., Cipriani, E., Lavitrano, M., & Ardizzoia, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914427 · Cited by 10
“It It is an inhibitor of CDK4, and it has been reported to be an accurate biomarker of pRb loss in di ff erent tumors [24,25]. an inhibitor of CDK4, and it has been reported to be accurate biomarker of pRb loss in different tumors [24,25]. p16 p16 ampli fi cation is frequently found in BC, and this…”
Chun, T.-Y., Wendell, D. L., Gregg, D. W., & Gorski, J. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00193-2 · Cited by 8
Clinical aspects of altered glycosylation of glycoproteins in cancer
Orntoft, T. F., & Vestergaard, E. M. (1999) · Electrophoresis · doi:10.1002/(sici)1522-2683(19990201)20:2<362::aid-elps362>3.0.co;2-v · Cited by 205
Self-citationLoss of functional pRB is not a ubiquitous feature of B-cell malignancies
Sinclair, A. J., & Frost, V. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690408 · Cited by 8
Role of Matrix and Cell Adhesion Molecules in Lens Differentiation
Menko, A. S., & Walker, J. L. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.011 · Cited by 8
Diagnostics of Epigenetic Alterations in Hereditary and Oncological Disorders
Zaletaev, D. V., Nemtsova, M. V., Strelnikov, V. V., Бабенко, О. В., Васильев, Е. В., Zemlyakova, V. V., Zhevlova, A. I., & Drozd, O. V. (2004) · Molecular Biology · doi:10.1023/b:mbil.0000023731.25512.fa · Cited by 8
“Nuclear protein p16 is known to regulate the activity of RB1 by preventing cyclin-dependent kinases (Cdk4/6) and cyclin D from forming a functional complex, which phosphorylates RB1 and releases transcription factor E2F from its complex with RB1 [ 30 ].”
BackgroundRubin, E., Tamrakar, S., & Ludlow, J. W. (1998) · Fetal and Pediatric Pathology · doi:10.1080/15513819809168797 · Cited by 8
Quinlan, R. A., & Prescott, A. R. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.008 · Cited by 8
p16INK4A-independence of Epstein–Barr virus-induced cell proliferation and virus latency
Hayes, M. J., Koundouris, A., Gruis, N. A., Bergman, W., Peters, G. G., & Sinclair, A. J. (2004) · Journal of General Virology · doi:10.1099/vir.0.79831-0 · Cited by 8
Self-citationFernández‐Marcelo, T., Morán, A., de Juan, C., Pascua, I. P., Head, J., Gómez, A. M., Hernándo, F., García‐Asenjo, J. A. L., Hernández, S., Sánchez-Pernaute, A., et al. (2012) · Oncology · doi:10.1159/000335678 · Cited by 11
Bai, Y., Lu, Z., Lin, Y., Sun, B., Wang, S., & Wang, G. (2013) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13786659070271 · Cited by 7
Sasaki, Y., Tsujiuchi, T., Murata, N., Kubozoe, T., Tsutsumi, M., & Konishi, Y. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00430-9 · Cited by 7
Lens Cell Proliferation: The Cell Cycle
Griep, A. E., & Zhang, P. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.009 · Cited by 15
TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage
Lee, M.-S., Lowe, G. N., Strong, D. D., Wergedal, J. E., & Glackin, C. A. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19991215)75:4<566::aid-jcb3>3.0.co;2-0 · Cited by 194
Effect of High-Dose Vitamin C on Tendon Cell Degeneration—An In Vitro Study
Ueda, S., Ichiseki, T., Shimasaki, M., Soma, D., Sakurai, M., Kaneuji, A., & Kawahara, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413358 · Cited by 6
Meza–Junco, J., Montaño‐Loza, A. J., & Aguayo-González, Á. (2006) · PubMed · Cited by 6
Xiong, Y., Wang, Y., Li, T., Yu, X., Zeng, Y., Xiao, G., Zhou, F., & Zhou, Y. (2021) · Journal of Cancer · doi:10.7150/jca.52909 · Cited by 7
“In conclusion, our investigation improves the study about the clinic correlation and function of cyclin D1, because it not only has the function of regulating the cell cycle and it is not necessary for pRB-negative cancer cells to proliferation such as HeLa [36, 37].”
BackgroundRegulation of the Cell Cycle and Interventional Developmental Therapeutics
Ivanchuk, S. M., & Rutka, J. T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50047-0 · Cited by 6
Prognostic biomarker in advanced gastric cancer
Mi, L., Ji, X., & Ji, J. (2016) · Translational gastrointestinal cancer · Cited by 6
Chuerduangphui, J., Pientong, C., Swangphon, P., Luanratanakorn, S., Sangkomkamhang, U. S., Tungsiriwattana, T., Kleebkaow, P., Burassakarn, A., & Ekalaksananan, T. (2018) · Medical Oncology · doi:10.1007/s12032-018-1151-2 · Cited by 6
Lee, D.-H., Yu, E., Aldahl, J., Yang, J., He, Y., Hooker, E., Le, V. L., Mi, J., Olson, A. W., Wu, H., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211153 · Cited by 7
Zhang, M., Li, B., Wang, J., Zhang, S., Li, H. Z., Ma, L., Guo, W., Lei, C., Chen, H., & Lan, X. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.013 · Cited by 6
XXYLT1 methylation contributes to the occurrence of lung adenocarcinoma
Zeng, H., Wang, Y., Wang, Y., & Zhang, Y. (2021) · Medicine · doi:10.1097/md.0000000000024150 · Cited by 6
Ahmad, M., Sun, Y., Jia, X., Li, J., Zhang, L., Yang, Z. R., Lin, Y., Zhang, X., Khan, Z. A., Qian, J., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.03.003 · Cited by 6
Kim, J. H., Kim, J. H., Yu, Y. S., Kim, D. H., Kim, Y. K., & Kim, K. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31816e232d · Cited by 7
“Wild type p16 arrests normal diploid cells in late G1, whereas a tumorassociated mutant of p16 does not.(24) Significantly, the ability of p16 to induce cell cycle arrest is lost in cells lacking functional RB.”
BackgroundPocket protein function in melanocyte homeostasis and neoplasia
Tonks, I. D., Hayward, N. K., & Kay, G. F. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00321.x · Cited by 6
Genetic Predisposition and Genetic Susceptibility
Merks, J. H. M., & Brecht, I. B. (2011) · Pediatric oncology · doi:10.1007/978-3-642-04197-6_6 · Cited by 6
Transcription Factors in Early Lens Development
Goudreau, G., Bäumer, N., & Gruß, P. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.004 · Cited by 6
Yang, T., Zhou, Q., Bei, Y., Meng, D., Ai, S., Zhang, Y., Zhang, J., Liu, L., Chen, H., Pan, X., et al. (2026) · EMBO Reports · doi:10.1038/s44319-025-00688-y · Cited by 5
“The protein p16 INK4a , encoded by the Cdkn2a gene, regulates cell cycle arrest and cellular senescence (Koh et al, 1995; Lukas et al, 1995; Mas-Bargues et al, 2017; Qiu et al, 2023), and its expression increases with age in animals (Baker et al, 2016) and humans (Li et al, 2011).”
Multi-scale system biology applied to cervical inter-epithelial neoplasia
Thiberville, C., Guillaud, M. D., Lockwood, W. W., Lam, W. L., Follen, M. M., & MacAulay, C. E. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.07.047 · Cited by 5
“Free E2F can thus recover its full transcription potential, enhancing cell proliferation [9,12].”
BackgroundKawai, Y., Nagayama, A., Miyao, K., Takeuchi, M., Yokoe, T., Kameyama, T., Wang, X., Seki, T., Takahashi, M., Hayashida, T., et al. (2024) · Breast Cancer · doi:10.1007/s12282-024-01641-y · Cited by 6
“The most well-characterized mechanism of action of CDK4/6 inhibitors is the inhibition of retinoblastoma protein (Rb) phosphorylation, resulting in the arrest of G1-S cell cycle transition in tumor cells [8, 9].”
EGASHIRA, A., Kanô, K., & Naito, K. (2011) · Journal of Reproduction and Development · doi:10.1262/jrd.10-170o · Cited by 6
Genes coding for cyclin-dependent kinase inhibitors are fragile in Xenopus
Tanaka, T., Ochi, H., Takahashi, S., Ueno, N., & Taira, M. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.06.019 · Cited by 9
Li, Q., Deng, C., Zhang, T., & Li, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168444 · Cited by 5
“In addition, the p16 gene is a cell cycle-related gene located on chromosome 9p21 and plays a key role in cell cycle regulation.(13,14) Preliminary reports have reported that GSTP1 and P16 promoter hypermethylation leads to the downregulation of gene expressions and contributes to an increase in the incidence of HBV-r…”
Morel, A. P., Unsal, K., Çağatay, T., Ponchel, F., Carr, B. I., & Öztürk, M. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80366-9 · Cited by 7
Zemlyakova, V. V., Strelnikov, V. V., Zborovskaya, I. B., Balukova, O. V., Maiorova, O. A., Васильев, Е. В., Zaletaev, D. V., & Nemtsova, M. V. (2004) · Molecular Biology · doi:10.1023/b:mbil.0000049856.44664.20 · Cited by 5
“its complex with RB1, and the cell passes from G1 to S [8].”
BackgroundGerber, A. N., & Tapscott, S. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3901 · Cited by 5
“However, there are many mechanisms that abrogate p16 cell cycle function, such as amplification of CDK4 or cyclin D1 or loss of Rb (26, 39).”
Rb Independent Inhibition of Cell Growth by p15INK4B
Aytac, U., Konishi, T., David, H., Mendoza, S., & Miller, C. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1164 · Cited by 5
Lack of p16 gene mutations in gastric cancers in Kashmir.
Bashir, S. A., Pandith, A. A., Yousuf, A., Parveen, N., Siddiqi, M. A., Muddassar, S., Andrabi, K. I., & Abdin, M. Z. (2010) · PubMed · Cited by 5
Carnero, A. (2000) · Revista de Oncología · doi:10.1007/bf02978297 · Cited by 6
Li, L., Tian, Y., & Lian, X. (2005) · Cancer Investigation · doi:10.1081/cnv-200058815 · Cited by 5
Oncogenes and Tumor Suppressor Genes in Cutaneous Malignant Melanoma
Albino, A. P., & Fountain, J. W. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb03058.x · Cited by 5
A novel L94Q mutation in the CDKN2A gene in a melanoma kindred
Stefanija, M. A., evar, M. H., Podkrajšek, K. T., Kr??i??nik, C., & Battelino, T. (2003) · Melanoma Research · doi:10.1097/00008390-200312000-00005 · Cited by 5
Huang, S.-M., Chen, H., Liu, L., Zhang, Y., Wang, J., Zhou, D., Fang, J., & Xu, L. (2024) · Hematology · doi:10.1080/16078454.2024.2439606 · Cited by 5
“The CDKN2A locus yields transcripts encoding p16 INK4a and p14 ARF , which modulate cell cycle progression, while CDKN2B, adjacent to CDKN2A, encodes p15, involved in inducing cell cycle arrest via the transforming growth factor-beta (TGF-beta) pathway [6–8].”
Michcik, A., Wojciechowska, B., Tarnawski, J., Choma, P., Polcyn, A., Garbacewicz, Ł., Sikora, M., Iacoviello, P., Wach, T., & Drogoszewska, B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020769 · Cited by 4
“However, p16 overexpression may also occur independently of HPV, driven by changes in CDKN2A, RB1, TP53, or CDK6 [36,37].”
Shu, S., Yamashita‐Kashima, Y., Yanagisawa, M., Nakanishi, H., Kodera, Y., Harada, N., & Yoshimura, Y. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000853 · Cited by 4
Zhang, F., Wang, Y., Wang, Y., Wang, X., Zhang, D., Zhao, X. Y., Jiang, R., Gu, Y., Yang, G., Fu, X., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4401 · Cited by 6
Disparity in the era of personalized medicine for epithelial ovarian cancer
Devlin, M.-J., & Miller, R. E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148024 · Cited by 7
Seki, Y., Koizumi, H., Koizuka, I., Takakuwa, T., & Tsutsumi, K. (2000) · Auris Nasus Larynx · doi:10.1016/s0385-8146(99)00057-7 · Cited by 4
Deletions of 9p21 and TP53 in bladder cancer
Park, W. S., Oh, M. J., Lee, H. K., Lee, K. O., Rhyu, M. G., Dong, S. M., Lee, J. Y., & Kim, S. H. (1996) · Journal of Korean Medical Science · doi:10.3346/jkms.1996.11.3.233 · Cited by 4
Growth Control by the Retinoblastoma Gene Family
Paggi, M. G., Felsani, A., & Giordano, A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:003 · Cited by 4
Primary Tumors of the Nervous System
Alvarez, A. A., & Bredel, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00131-2 · Cited by 5
Wu, R. T. Y., & Cheng, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418680-4.00021-x · Cited by 4
Molecular Genetics of Lung and Pleural Neoplasms
Cagle, P. T., Jagirdar, J. S., & Popper, H. (2008) · Springer eBooks · doi:10.1007/978-0-387-72114-9_2 · Cited by 4
Emerging patterns and implications of breast cancer epigenetics
Venkatesh, T., Thankachan, S., Kabekkodu, S. P., Chakraborti, S., & Suresh, P. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819753-0.00015-5 · Cited by 7
Nurwidyaningtyas, W., Sargowo, D., Sandra, F., & Wihastuti, T. A. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00117 · Cited by 3
Nishikawa, T., Hara, R., Ito, Y., Masuno, K., Tominaga, K., Wato, M., Watanabe, Y., Mori, M., & Tanaka, A. (2005) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.38.53 · Cited by 3
Li, L., & Tian, Y. (2003) · Colloids and Surfaces B Biointerfaces · doi:10.1016/s0927-7765(03)00114-0 · Cited by 3
Nishioka, M., Win, S. S., Myint, B., & Takagi, M. (2003) · Oral Medicine & Pathology · doi:10.3353/omp.8.7 · Cited by 3
“This complex promotes the phosphorylation of Rb and the release of transcriptional factor, which accelerates the cell cycle (4, 9, 10).”
Backgroundde Paula, A. M. B., Cardoso, S. V., & Gomez, R. S. (2006) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.1590/s1676-24442006000400010 · Cited by 4
Serine/threonine-specific protein phosphatases and cancer
Berndt, N. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.5.581 · Cited by 4
Rio‐Tsonis, K. D., & Eguchi, G. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.013 · Cited by 6
The Growth-Inhibitory Effects of TGFβ
Herrera, R. E. (1998) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-72149-6_2 · Cited by 3
The retinoblastoma protein: More than meets the eyes
Skapek, S. X., Qian, Y., & Lee, E. Y.-H. P. (1997) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(96)00033-x · Cited by 3
(1998) · doi:10.1002/(sici)1098-2744(199806)22:2<128::aid-mc8>3.0.co;2-i
Molecular Genetics of Tumors of the Central Nervous System
James, C. D. (2005) · Humana Press eBooks · doi:10.1385/1-59259-843-9:019 · Cited by 4
Malkin, D. M., & Barlow, J. W. (2001) · Informa Healthcare eBooks · doi:10.1201/9780203904237.ch1 · Cited by 3
Toumasis, P. N., Mallipatna, A. C., Corson, T. W., & Dimaras, H. (2025) · Pediatric Investigation · doi:10.1002/ped4.12472 · Cited by 2
“50,51 Hence, pathogenic variants in the RB1 gene that result in the dysfunction or absence of pRB lead to the perpetual activation of E2Fs and persistent stimulation of the cell cycle, significantly contributing to tumor development.”
Abdulkader, I., Ruibal, Á., Cameselle‐Teijeiro, J., Gudé, F., León‐Mateos, L., Arce-Calisaya, P., Sánchez-Salmón, A., & Forteza, J. (2009) · The Open Pathology Journal · doi:10.2174/1874375700903010033 · Cited by 2
“[20] showed that wildtype p16 arrests normal diploid cells in late G1, whereas a tumor-associated mutant of p16 does not.”
BackgroundHereditary predisposition to uveal melanoma
Abdel‐Rahman, M. H., Pilarski, R., Fatehchand, K., Davidorf, F. H., & Cebulla, C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00009-5 · Cited by 2
Nanobodies restore stability to cancer-associated mutants of tumor suppressor protein p16INK4a
Burbidge, O., Pastok, M. W., Papini, D., Hodder, S. L., Zenkevičiūtė, G., Tan, K. Z. J., Turberville, S., Noble, M. E. M., Endicott, J., & Itzhaki, L. S. (2025) · Structure · doi:10.1016/j.str.2025.07.017 · Cited by 3
Cell Cycle Control and Check Points in Hematopoietic Stem Cells
Ruscetti, F. W., & Bartelmez, S. H. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50100-0 · Cited by 2
Immortalization of Hepatocytes through Targeted Deregulation of the Cell Cycle
Jennings, G. S., & Strauss, M. (2007) · Springer eBooks · doi:10.1007/978-0-585-37971-5_10 · Cited by 2
Self-citationGrowth Factors, Signal Transduction Pathways, and Tumor Suppressor Genes in Esophageal Cancer
Zare, M., Moghanibashi, M., & Rastgar, F. (2012) · InTech eBooks · doi:10.5772/30333 · Cited by 2
Familial Melanoma in Italy: A Review
Funari, G., Menin, C., Elefanti, L., D’Andrea, E., & Chiara, M. L. D. (2011) · InTech eBooks · doi:10.5772/21801 · Cited by 2
“…are needed for the interaction of p16 with its target: p16 binds to CDK4/6 (Cyclin-Dependent Kinases) and inhibits the catalytic activity of cyclin D-CDK4/6 complexes, hence maintaining the oncosuppressor pRb in its hypo-phosphorilated state (Lukas et al., 1995), thus preventing G1/S transition.”
BackgroundLeder, A., McMenamin, J., Zhou, F., Moran, J. L., Beier, D. R., & Leder, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210866 · Cited by 2
Alotaibi, F., & Alrashed, H. (2015) · Cited by 2
BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer
Al‐Moghrabi, N. (2017) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2017.01.004 · Cited by 2
Molecular Pathology and Genomics of Melanoma
Griewank, K., Murali, R., & Wiesner, T. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_41-1 · Cited by 2
Li, S., & Zou, H. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00201-9 · Cited by 2
Molecular Pathology and Genomics of Melanoma
Griewank, K., Murali, R., & Wiesner, T. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_41 · Cited by 3
Inferring genomic loss and location of tumor suppressor genes from high density genotypes
Wang, H., Lee, Y., Nelson, S. F., & Sabatti, C. (2005) · eScholarship (California Digital Library) · Cited by 2
Proapoptotic Strategy in Cancer Gene Therapy
Holman, D. H., Hyer, M. L., El-Zawahry, A. M., Keller, G. M., & Norris, J. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-785-7_18 · Cited by 2
Kistler, J., Eckert, R., & Donaldson, P. J. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.007 · Cited by 2
Tumor Suppressor Gene Therapy for Brain Tumors
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., & Yung, W. K. A. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-478-8_12 · Cited by 2
Inactivation of Negative Growth Regulators During Neoplastic Transformation
Smolinski, K. N., & Meltzer, S. J. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-125-1_5 · Cited by 2
ASSOCIATION OF DNA METHYLATION AND ORAL CANCER RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS
Rapado‐González, Ó., Sevilla-García, C. I., Pizcueta-Leirós, J., Salgado‐Barreira, Á., Piñeiro‐Lamas, M., Villafranca, F. D. C., López‐López, R., & Suárez‐Cunqueiro, M. M. (2025) · Journal of Evidence Based Dental Practice · doi:10.1016/j.jebdp.2025.102169 · Cited by 1
Mechanistic modeling of cell viability assays with in silico lineage tracing
Mutsuddy, A., Huggins, J. R., Amrit, A. K., Harley-Gasaway, A. M., Erdem, C., Jones, E. T., Laurine, O. G., Calhoun, J. C., & Birtwistle, M. R. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013156 · Cited by 1
“One of the known resistance mechanisms of CDK4/6 inhibition is the loss of Rb function [89,90].”
Genetics and Epigenetics of Head and Neck Cancer
Shaw, R., & Dhanda, J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_5 · Cited by 1
Regulators of Cardiac Cell Growth, Differentiation, and Apoptosis
Kirshenbaum, L. A., & de Moissac, D. (1997) · Heart Failure Reviews · doi:10.1023/a:1009724128699 · Cited by 2
“However, it appears that p16 function may be contingent on the presence of a functional Rb [ 68 ,69].”
BackgroundKamb, A., & McCormack, K. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-230-2_8 · Cited by 1
Immunohistochemistry in the Diagnosis of Squamous Intraepithelial Lesions of the Uterine Cervix
Evanthia, A., & Koukoulis, G. Κ. (2012) · InTech eBooks · doi:10.5772/29219 · Cited by 2
“…kinase inhibitor. p16 decelerates the cell cycle and functions as a tumor suppressor, while having a role in cellular senescence. p16 affects pRb-mediated regulation of the G1/S transition (Lukas et al., 1995; Ohtani et al., 2004; Quelle et al., 1995; Serrano, 1997; Sano et al., 1998).”
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.